Trainee (Relationship between study population,subgroup analyses & indication for cancer medicines)
Selection procedure reference: EMA/TR/10911
Deadline for applications: 6 May 2025 23:59 CET
The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU), located in Amsterdam. It began operating in 1995. It is responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU.
This traineeship opportunity is now open for applications until 6 May 2025 23:59 CET, with an intake on 1 October 2025.
About the traineeship programme
The Agency is looking for motivated, qualified recent graduates or students on an Erasmus+ or other programme or PhD students or Master's students (who posses a previous degree), who are interested in gaining experience and contribute to the Agency’s work for every patient in Europe. The purpose of a traineeship at the Agency is to perform tasks that are predominantly in the interest of the trainee’s training and principally serve to increase the trainee’s knowledge and to gain relevant experience.
Placement description
We are looking for a trainee in the Therapeutic Areas Department.
Specific objectives and projects
Recent developments in cancer diagnosis and treatment have dramatically improved survival rates and quality of life for cancer patients, with cancer medicines representing the therapeutic area with the most number of approvals.
Since further development and spending on cancer drugs are expected to continue to rise, and as the joint clinical assessments are kicking off with cancer medicines, it is important to take stock of the experience to understand the relationship between the clinical data (focusing on study population and subgroup analyses) and the finally agreed indication to further inform future assessments and potentially better alignment between regulatory and reimbursement decisions.
The trainee will be expected, with support from relevant colleagues, to identify products in scope and retrieve, from their assessment reports, the discussion and rationale for the agreed indication, as well as the details of the clinical data provided specifically with regard to the studied patient population and subgroup analyses; the trainee will then be expected to evaluate the impact of such elements and draw learnings as part of a report or a potential publication.
Learning outcomes
Through this work, the trainee will:
- gain insight in the review and approval of cancer medicines,
- familiarise themselves with the centralised procedure review process and EU regulatory framework,
- enhance existing skills in data analysis, scientific writing and communication.
Eligibility criteria
To be eligible for consideration for this placement, you are required to:
- enjoy full rights as a citizen of a European Union Member State or Iceland, Lichtenstein and Norway;
- possess a university degree in pharmacy, medicine or life sciences (minimum of three years or more) that must have been obtained between 6 May 2024 and 6 May 2025 or be a university student on an Erasmus + or a similar programme or a PhD student or a Master's student with a previous fully finished degree in the areas mentioned before.
- a thorough knowledge of English (at least level C1) and good knowledge of other official EU language (at least B2) of the Common European Framework for Languages
For criteria 1 and 2, you will be required to provide proof in the application form and at the interview stage. Failing to present these documents may result in the disqualification from the procedure.
Additional skills
- Good analytical and communication skills.
- It is an advantage if you already have existing knowledge in cancer and/or medical statistics.
Behavioural Competencies
You will demonstrate the following behavioural competencies:
- Communication skills
- Interpersonal skills
- Working with others
- Adaptability
- Research and analytical skills
- Learning and development
Expected selection timelines
Deadline for applications | 6 May 2025 23:59 CET |
---|---|
Assessments (remote) | From end of June 2025 to mid-July 2025 |
Decision and offers | By end of July 2025 |
Placement start | 1 October 2025 |
Conditions of traineeship
The traineeship is offered for 10 months (1 October 2025 – 31 July 2026) and takes place at the Agency’s premises in Amsterdam with possibility for teleworking up to 40% of working time from The Netherlands and occasional teleworking from outside The Netherlands. Traineeships are offered for either full-time or part-time (80% or 50%) if combined with university studies.
The Agency pays a monthly stipend of €1,942.19 for a full-time traineeship (reduced accordingly for 80% or 50%) and a travel contribution upon joining the Agency.
Each trainee will have a mentor at the Agency who will guide the trainee through the programme.
The conditions of employment are stated in the Executive Decision on rules governing the traineeship programme at the EMA available here.
______________________________________________________________________________________________________
Domenico Scarlattilaan 6 - 1083 HS Amsterdam - The Netherlands
Telephone +31 (0)88 781 6000 - Email recruitment@ema.europa.eu
© European Medicines Agency, 2024. Reproduction is authorised provided the source is acknowledged.
Job Segment:
Law, Pharmacy, Data Analyst, Trainee, Legal, Healthcare, Data, Entry Level, Research